drugset / Trial / NCT05515029
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Phase 3
Active not recruiting
56 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Timeline
- Start
- 2022-08-23
- Primary completion
- 2024-08-15
- Completion
- 2026-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 10 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 100 mg/kg | — |
| Subject | Vedolizumab | Monoclonal antibody | 10 mg/kg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | — |
| Background | Tacrolimus | Small molecule | 3 mg/kg | — |